Figure 4a:

BAT activation in humans with β3-adrenergic receptor agonist mirabegron. Twelve subjects underwent ¹⁸F-FDG PET after administration of either placebo or 200-mg mirabegron. (a) ¹⁸F-FDG PET images in 21-year-old man after administration of placebo (left) and mirabegron (right). There are multiple sites of BAT uptake after mirabegron administration. (b) Graph shows results from all 12 patients. There is a significant increase in detectable BAT after mirabegron administration. Patient identification numbers are listed on graph. (Reprinted, with permission, from reference 9.)